A US S&P 500Russell 1000 Earnings call

Agilent Technologies (A) · Q2 2026 results and valuation

Share price: $176.95 · 2026-11-11

Results Q2 2026 vs Q1 2026 · previous quarter · fiscal Q3 2026

Net income up 6.8% on the previous quarter, guidance raised. Tone in line with last period.

Only a basic analysis is available for this company at the moment.

1 · Numbers

+6.8%

Net income vs Q1 2026

Guidance raised

Net income 362.0M vs 339.0M

Revenue +2.3%

2 · How management spoke

Unchanged

Language tone vs last period

Language: very upbeat — about as upbeat as in Q1 2026.

3 · What stood out

Agilent Technologies raised its full-year EPS guidance by $0.15 at midpoint to a range of $6.18 to $6.21.

Valuation

Is Agilent Technologies undervalued?

Reverse DCF. Free cash flow from the last full fiscal year (2025-10-31), grown for 10 years, discounted back, plus a terminal value. “Implied growth” is the rate the current price assumes.

At 0.5% growth a year (3-year revenue growth), the model's fair value is $43.76 a share — the stock trades 304% above it. Today's price assumes 18.6% growth a year.

Current price

$176.95

close of 2026-11-11

Market implies growth of iThe yearly free-cash-flow growth, for the next 10 years, that today’s share price already assumes. If you believe the company grows faster than this, the stock is cheap under this model; slower, and it is expensive.

+18.6% for 10 yrs

Fair value / share

$43.76

Buy below

$32.82

Price vs fair value

Overvalued >200%

Price vs buy-below price

Overvalued >200%

Official channels

The company's own website and social media accounts.

Read between the lines

  1. Guidance

    Based on the strong performance, Agilent Technologies now expects fiscal year '26 revenue to be in the range of $7.49 billion to $7.51 billion on a reported basis.

  2. Figure

    Agilent's Q3 revenue reached $1.88 billion, growing 7.3% on a core basis and surpassing guidance, driven by strong underlying demand.

    Source quote
    “For the third quarter, Agilent reported $1.88 billion in revenue, growing 7.3% on a core basis and exceeding the high...”
  3. Fading

    CAM growth excluding China reached the low teens even as H1 momentum faded.

    Source quote
    “So after a strong high single digit growth in H1, we are going to see how it plays out with The Middle... And we had actually low teens CAM growth ex China. And it is really driven by a number of things.”

Tone

How upbeat the language was, compared with other companiesiTone counts positive minus negative finance words, adjusted for length. Executives mostly speak positively, so the labels compare each call with every company's latest call: “typical” is the middle third, “very upbeat” the top tenth, “cautious” the bottom tenth.. Dot: Q2 2026. Ring: Q1 2026.

Overall language Very upbeat (was upbeat)

Very upbeat — about as upbeat as in Q1 2026.

Sentences that drove the tone
“Our largest end markets continue to improve, and our teams are converting that improvement into results through strong commercial execution, while a differentiated portfolio and best-in-class service drive share gain.”
“But we see strong momentum into China continuing to the year-end, and we're increasing our guide from high mid-single digits from flat and our Q4 guidance is high single digits.”
“Based on strong results year-to-date and our outlook for the fourth quarter, we are raising our full year expectations for CAM from mid- to high to high single-digit growth.”

Full figures

USD · SEC EDGAR XBRL (10-Q, period end 2026-07-31)

Metric Q2 2026period end 2026-07-31 Q1 2026period end 2026-04-30 Change Q2 2025 YoY
Revenue 1.88B 1.83B +2.3% 1.74B +8.1%
Operating income 444.0M 399.0M +11.3% 360.0M +23.3%
Net income 362.0M 339.0M +6.8% 336.0M +7.7%
EPS 1.28 1.20 +6.7% 1.18 +8.5%
P/E today 33.8 27.3 23.2 +4.1 26.8 +0.5

Topics

Most discussed now

  • Within pharma, biotech grew double digits and small molecule grew mid-single digits.
  • Moreover, the recent close of the Biocare transaction in late June builds on that momentum by expanding Agilent Technologies' clinically…
  • The improving end market picture was complemented by a notable step-up in China, which grew 9%, well ahead of Agilent Technologies'...
  • Core or organic constant currency revenue growth is adjusted for the impact of currency exchange rates and any acquisitions and...
  • Agilent Technologies' operating margin of 27.2%, excluding the net benefit from tariff refunds, was 80 basis points ahead of its implied...

Faded since Q1 2026

  • Fading Agilent Technologies has seen the normal trajectory of the replacement cycle, but continued momentum and funnels are up really strong.
  • Fading Of all, Agilent Technologies is delighted with the results, a really strong result from the team where it is taking share...
  • Fading Notably, Agilent Technologies recently achieved mechanical completion of its train c build out.
  • Fading Of course, customer focused innovations are compelling...

Latest announcements

Official filings, newest first.